These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21290086)

  • 1. Serious adverse events reporting on systemic terbinafine: a Danish register-based study.
    Bangsgaard N; Saunte DM; Folkenberg M; Zachariae C
    Acta Derm Venereol; 2011 May; 91(3):358-9. PubMed ID: 21290086
    [No Abstract]   [Full Text] [Related]  

  • 2. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis.
    Kejda J
    Postgrad Med; 1999 Jul; Spec No():12-5. PubMed ID: 10492661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Terbinafine-induced persistent agueusia: first reported case].
    Schmutz JL; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 2000 Mar; 127(3):341. PubMed ID: 10804319
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week).
    Takahata Y; Hiruma M; Shiraki Y; Tokuhisa Y; Sugita T; Muto M
    Mycoses; 2009 Jan; 52(1):72-6. PubMed ID: 18444971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus.
    Gupta AK; Gover MD; Lynde CW
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1188-93. PubMed ID: 17062029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The modern approach to the treatment for onychomycosis of hands and feet in the outpatient setting].
    Gerasimchuk EV; Gerasimov VV; Molchanov BA
    Voen Med Zh; 2005 Nov; 326(11):44-5. PubMed ID: 16404907
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombocytopenia associated with oral terbinafine.
    Grunwald MH
    Int J Dermatol; 1998 Aug; 37(8):634. PubMed ID: 9732018
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis.
    Gupta AK; Lynch LE; Kogan N; Cooper EA
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):256-62. PubMed ID: 19438818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison.
    Sigurgeirsson B; Elewski BE; Rich PA; Opper C; Cai B; Nyirady J; Bakshi R
    J Dermatolog Treat; 2006; 17(1):38-44. PubMed ID: 16467022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient.
    Aguilar C; Mueller KK
    J Am Acad Dermatol; 2001 Oct; 45(4):632-4. PubMed ID: 11568763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of pulse therapy with terbinafine tablets and topical terbinafine cream for the treatment of dermatophyte onychomycosis: a pilot study.
    Nakano N; Hiruma M; Shiraki Y; Chen X; Porgpermdee S; Ikeda S
    J Dermatol; 2006 Nov; 33(11):753-8. PubMed ID: 17073989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.
    Warshaw EM; Fett DD; Bloomfield HE; Grill JP; Nelson DB; Quintero V; Carver SM; Zielke GR; Lederle FA
    J Am Acad Dermatol; 2005 Oct; 53(4):578-84. PubMed ID: 16198776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature.
    Beltraminelli HS; Lerch M; Arnold A; Bircher AJ; Haeusermann P
    Br J Dermatol; 2005 Apr; 152(4):780-3. PubMed ID: 15840114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study.
    Amichai B; Nitzan B; Mosckovitz R; Shemer A
    Br J Dermatol; 2010 Jan; 162(1):46-50. PubMed ID: 19785609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for cure following treatment of onychomycosis.
    Sigurgeirsson B
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):679-84. PubMed ID: 19929941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
    Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
    Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of terbinafine on onychomycosis with a 2 year follow-up].
    Shibaki H
    Nihon Ishinkin Gakkai Zasshi; 2007; 48(4):153-8. PubMed ID: 17975530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial.
    Tavakkol A; Fellman S; Kianifard F
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):1-13. PubMed ID: 16730616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis.
    Arca E; Taştan HB; Akar A; Kurumlu Z; Gür AR
    J Dermatolog Treat; 2002 Mar; 13(1):3-9. PubMed ID: 12006131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new oral antifungal agents for onychomycosis of the toenails.
    Gupta AK; Shear NH
    J Eur Acad Dermatol Venereol; 1999 Jul; 13(1):1-13. PubMed ID: 10565624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.